Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by Philip Barter
Total Records ( 1 ) for Philip Barter
  Scott M. Grundyemail , Hidenori Arai , Philip Barter , Thomas P. Bersot , D. John Betteridge , Rafael Carmena , Ada Cuevas , Michael H. Davidson , Jacques Genest , Y. Antero Kesaniemi , Shaukat Sadikot , Raul D. Santos , Andrey V. Susekov , Rody G. Sy , S. LaleTokgozoglu , Gerald F. Watts and Dong Zhao
  An international panel of the International Atherosclerosis Society has developed a new set of recommendations for the management of dyslipidemia. The panel identifies non-high-density lipoprotein cholesterol as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for subjects at greater risk. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility